Tags

Type your tag names separated by a space and hit enter

[Establishment of therapeutic goal and plan of gout and asymptomatic hyperuricemia].
Nihon Rinsho. 2008 Apr; 66(4):729-35.NR

Abstract

Gout is a crystal deposition disease. European and Japanese guidelines of management for gout recommend that serum urate concentration should be maintained below 6.0 mg/dL to promote crystal dissolution leading to prevention of recurrent gouty attack. Although allopurinol is recommended to be an adequate drug for urate lowering therapy in all gouty patients by European guideline, it is desirable that allopurinol is indicated in patients with overproduction type and benzbromarone in patients with underexcretion type, recommended by Japanese guideline. Asymptomatic hyperuricemia dose not equate to gout. As there is no evidence to support treatment of isolated hyperuricemia with urate lowering therapy currently, it is difficult to establish lowering goal of serum urate level in patients with asymptomatic hyperuricemia. Advice regarding lifestyle and treatment of associated comorbidity should be preferred to urate lowering therapy. However, urate lowering therapy may be indicated in high risk patients with hyperuricemia who are suffered from hypertension, diabetes mellitus, ischemic heart disease and renal insufficiency.

Authors+Show Affiliations

Fujimori S
Department of Internal Medicine, Teikyo University School of Medicine.

MeSH

AllopurinolBenzbromaroneCardiovascular DiseasesGoutGout SuppressantsHumansHyperuricemiaLife StylePatient Care PlanningPractice Guidelines as TopicRenal InsufficiencyUric Acid

Pub Type(s)

English Abstract
Journal Article
Review

Language

jpn

PubMed ID

18409523

Citation

Fujimori, Shin. "[Establishment of Therapeutic Goal and Plan of Gout and Asymptomatic Hyperuricemia]." Nihon Rinsho. Japanese Journal of Clinical Medicine, vol. 66, no. 4, 2008, pp. 729-35.
Fujimori S. [Establishment of therapeutic goal and plan of gout and asymptomatic hyperuricemia]. Nihon Rinsho. 2008;66(4):729-35.
Fujimori, S. (2008). [Establishment of therapeutic goal and plan of gout and asymptomatic hyperuricemia]. Nihon Rinsho. Japanese Journal of Clinical Medicine, 66(4), 729-35.
Fujimori S. [Establishment of Therapeutic Goal and Plan of Gout and Asymptomatic Hyperuricemia]. Nihon Rinsho. 2008;66(4):729-35. PubMed PMID: 18409523.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Establishment of therapeutic goal and plan of gout and asymptomatic hyperuricemia]. A1 - Fujimori,Shin, PY - 2008/4/16/pubmed PY - 2008/5/31/medline PY - 2008/4/16/entrez SP - 729 EP - 35 JF - Nihon rinsho. Japanese journal of clinical medicine JO - Nihon Rinsho VL - 66 IS - 4 N2 - Gout is a crystal deposition disease. European and Japanese guidelines of management for gout recommend that serum urate concentration should be maintained below 6.0 mg/dL to promote crystal dissolution leading to prevention of recurrent gouty attack. Although allopurinol is recommended to be an adequate drug for urate lowering therapy in all gouty patients by European guideline, it is desirable that allopurinol is indicated in patients with overproduction type and benzbromarone in patients with underexcretion type, recommended by Japanese guideline. Asymptomatic hyperuricemia dose not equate to gout. As there is no evidence to support treatment of isolated hyperuricemia with urate lowering therapy currently, it is difficult to establish lowering goal of serum urate level in patients with asymptomatic hyperuricemia. Advice regarding lifestyle and treatment of associated comorbidity should be preferred to urate lowering therapy. However, urate lowering therapy may be indicated in high risk patients with hyperuricemia who are suffered from hypertension, diabetes mellitus, ischemic heart disease and renal insufficiency. SN - 0047-1852 UR - https://www.unboundmedicine.com/medline/citation/18409523/[Establishment_of_therapeutic_goal_and_plan_of_gout_and_asymptomatic_hyperuricemia]_ DB - PRIME DP - Unbound Medicine ER -